EX-99.1 10 meso-ex991_373.htm EX-99.1 meso-ex991_373.htm

 

Exhibit 99.1

Appendix 4E

Preliminary final report for the twelve months to 30 June 2022

 

Name of entity

MESOBLAST LIMITED

ABN 68 109 431 870

 

1.

Reporting period

 

Report for the financial year ended

30 June 2022

Previous corresponding period is the financial year ended

30 June 2021

 

2.

Results for announcement to the market

 

 

Up/down

% change

 

Amount reported for the year ended 30 June 2022

USD’000

Revenues from ordinary activities (item 2.1)

 

Up

37%

to

10,214

Loss from ordinary activities after tax attributable to members (item 2.2)

Down*

8%

to

91,347

 

 

 

 

 

Net loss for the period attributable to members (item 2.3)

Down*

8%

to

91,347

*decrease in loss

 

 

 

 

 

 

 

 

 

There are no dividends being proposed or declared for the period (item 2.4 and 2.5)

 

 

 

 

 

Commentary related to the above results

 

 

 

 

Please refer to ‘Item 5.A Operating results’ within the Form 20-F for the year ended 30 June 2022.

 

 

3.

Net tangible assets per security

 

 

30 June 2022

30 June 2021

Net tangible (liability)/asset backing

per ordinary security (in USD cents)

(10.18) cents

2.64 cents

 

A large proportion of the Company’s assets are intangible in nature, consisting of goodwill, acquired licenses to patents, in-process research and development acquired, currently marketed products and right-of-use assets.  Our intangible assets primarily relate to the acquisition of both Mesoblast, Inc and the culture-expanded Mesenchymal Stem Cell technology. These assets and the associated provision for contingent consideration are excluded from the calculation of net tangible assets per security. As at June 30, 2022 and 2021, the value of deferred tax liabilities was $Nil.

 

 


 

 

4.

Other documents accompanying this Appendix 4E

This Appendix 4E should be read in conjunction with the Mesoblast annual report on the form 20-F, which includes:

 

-

Item 18 Financial Statements; and

 

-

Other sections as tabled below.

This preliminary final report and the associated Directors’ Report are found throughout the various sections of the accompanying Mesoblast annual report on the form 20-F.

The following table has been provided to assist readers to locate each section of the Directors’ Report within the accompanying annual report on the form 20-F.

 

Sections of Directors’ Report

Form 20-F Reference

Principal activities

Item 5.A Operating Results

See subheading – “Financial Overview”

Review of operations and activities

Item 4.B Business Overview

Item 5.A Operating Results

Business strategies and prospects for future years

 

Item 4.B Business Overview

 

Business risks

Item 3.D Risk Factors

Significant changes in the state of affairs

Item 5.A Operating Results

See subheading – “Significant changes in the state of affairs”

Matters subsequent to the end of the financial year

Item 8.B Significant Changes

Likely developments and expected results of operations

Item 5.A Operating Results

See subheading – “Likely developments and expected results of operations”

Environmental regulations

Item 5.A Operating Results

See subheading – “Environmental regulations”

Dividends

Item 4.B Business Overview

See subheading – “Dividends”

Information on directors

Item 6.A Key Management Personnel

See subheading – “Details of Directors and Senior Management”

Remuneration report

The Remuneration report starts at Item 6 and ends part way through Item 6.B as indicated

Indemnification of officers

Item 6.B Compensation

See subheading – “Indemnification of officers”

Proceedings on behalf of the group

Item 6.B Compensation

See subheading – “Proceedings on our behalf”

Non-Audit Services

Item 6.B Compensation

See subheading – “Non-audit services”

Auditor’s independence declaration

Exhibits 99.2

Directors’ Resolution

Item 6.B Compensation

See subheading – “Directors’ resolution”

 


 

 

 

5.

Audited Financial Report 2022

This preliminary final report has been based on accounts which have been audited.  The independent auditors report includes the following statement:

We draw attention to Note 1(i) in the financial report, which indicates that the Group had net cash outflows from operating activities of $65.8 million and the ability of the Group to continue as a going concern is dependent on the Group obtaining financing from one or more sources. These conditions, along with other matters set forth in Note 1(i), indicate that a material uncertainty exists that may cast significant doubt on the Group’s ability to continue as a going concern. Our opinion is not modified in respect of this matter.

A copy of the audited Financial Statements for the year ended 30 June 2022 is included in Item 18 Financial Statements within the Form 20-F.

-     End of Appendix 4E     -